

## SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011) (Company Registration Number: 201134046D)

## PROFIT WARNING ON THE UNAUDITED FINANCIAL RESULTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2024

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to inform shareholders that following a preliminary review of the Group's unaudited financial results for the financial year ended 30 June 2024 ("**FY2024**"), the Group is expected to report a significant net loss after tax for FY2024 as compared to a net loss after tax for the financial year ended 30 June 2023.

As described in the risk factors outlined in the Group's offer document, the Group incurred loss after tax in FY2023 following the continued development and expansion of the business operations and there is a risk that the Group may continue reporting losses. Based on a preliminary review of the unaudited financial results of the Group, the Board expects the Group to report a significant net loss after tax for FY2024. This is mainly attributable to the Group's slower than expected ramp-up in its business operations, that may result in an impairment to its assets.

The Company is in the process of finalising its unaudited financial results for FY2024. Further details of the Group's financial performance will be disclosed when the Company announces its unaudited financial results for FY2024 on or before 29 August 2024.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the Company's shares. When in doubt, shareholders and potential investors are advised to seek independent advice from their professional advisors before trading or making any investment decision on the Company's shares.

## BY ORDER OF THE BOARD

Dr Djeng Shih Kien Executive Director and Chief Executive Officer 31 July 2024

Singapore Institute of Advanced Medicine Holdings Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("SGX-ST") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.